Aizant Drug Research Solutions Pvt Ltd

10/05/2026

We celebrate the love, strength, and care that mothers bring into our lives every day. Their resilience, compassion, and unwavering support continue to inspire generations both at home and beyond.

At Aizant, we value and support motherhood by fostering a caring and inclusive work environment that empowers working mothers every day.

Wishing all mothers a joyful and heartfelt Mother’s Day.

05/05/2026

Asthma continues to impact millions worldwide, highlighting the importance of timely care and effective treatment.

The future of respiratory care depends on how well therapies are developed and delivered.

At Aizant, integrated CDMO capabilities support the development of consistent and reliable respiratory treatments, helping expand access globally.

On World Asthma Day, the focus remains on enabling better outcomes through stronger development foundations.
bd@aizant.com | www.aizant.com

05/05/2026

At Aizant, we enable seamless API synthesis through integrated development capabilities, from route scouting to process optimization and scale-up. Our approach is designed to support formulation success with consistent quality, regulatory alignment, and scalable manufacturing readiness.

With a focus on innovation, compliance, and efficiency, we help accelerate your journey from development to commercialization while ensuring global regulatory expectations are met.

Connect with us to strengthen your product pipeline with reliable API synthesis expertise.
bd@aizant.com | www.aizant.com

01/05/2026

Every milestone we achieve is powered by the dedication, skill, and commitment of our people.

On this Labor Day, we celebrate the individuals behind the progress—those who contribute every day to making medicines more accessible across the globe.

At Aizant, it’s their passion and perseverance that drive meaningful impact, from development to delivery.

Wishing everyone a Happy Labor Day.

29/04/2026

We are proud to receive U.S. FDA approval for Generic Eltrombopag Tablets across multiple strengths, reinforcing our commitment to enabling reliable and efficient drug development.

Developed through Aizant’s integrated Concept Cycle, this achievement reflects a seamless journey from molecule selection to market readiness, driven by in-house capabilities across R&D, manufacturing, and regulatory expertise.

Approved in the first review cycle through the ANDA pathway, this milestone underscores the strength of our end-to-end development approach and our ability to deliver with speed, quality, and consistency.

At Aizant, we continue to focus on building differentiated products and delivering value across the pharmaceutical lifecycle.

Learn more at www.aizant.com
For business enquiries: bd@aizant.com

27/04/2026

We are pleased to receive approval for Apixaban Tablets, 5 mg, in the Philippines, reinforcing our commitment to expanding global access in the area of anticoagulants.

Developed through Aizant’s integrated drug development approach, this achievement reflects a seamless journey from formulation to market readiness, driven by in house capabilities across R&D, manufacturing, and regulatory expertise.

At Aizant, we continue to focus on building differentiated products and delivering value across the pharmaceutical lifecycle.

Learn more at www.aizant.com
For business enquiries, write to bd@aizant.com

25/04/2026

Progress in the fight against malaria is one of the most meaningful achievements in global health, and it continues to move forward.

Since 2000, an estimated 2.3 billion malaria cases have been averted, and 14 million lives have been saved. Today, 47 countries have been certified malaria free, reflecting what sustained global efforts across research, prevention, and treatment can achieve.

At the same time, malaria continues to impact millions of lives, reminding us that the journey is not yet complete.

Sustaining this progress depends on how effectively we continue to translate research into real world solutions. Strong drug development ecosystems, scalable manufacturing, and improved access will play a critical role in shaping the next phase of impact.

At Aizant, we remain committed to supporting this journey through our integrated capabilities across development, manufacturing, and clinical research, helping bring therapies closer to patients who need them.

Because progress is not just about what we have achieved, but how consistently we continue to move forward.

World Malaria Day

Source: WHO World Malaria Report 2025

22/04/2026

This World Earth Day, we reflect on how each stage of drug development can contribute to a healthier planet.

At Aizant, sustainability is integrated into how we design, develop, and manufacture, embracing practices like green chemistry, energy optimization, and digital transformation to reduce environmental impact.

Because a healthier future depends on both better medicines and a healthier planet.

21/04/2026

A significant milestone achieved at Aizant Drug Research Solutions.

We are proud to receive U.S. FDA approval for Generic Selexipag Tablets across multiple strengths, reinforcing our commitment to enabling reliable and efficient drug development.

Developed through Aizant’s integrated Concept Cycle, this achievement reflects a seamless journey from molecule selection to market readiness, driven entirely by in house capabilities across R&D, manufacturing, and clinical support.

With 180 days of exclusivity in the U.S. and a Day 1 launch with our valued partner, this approval highlights the strength of our end to end development approach and our ability to accelerate time to market.

At Aizant, we continue to focus on building differentiated products and delivering value across the pharmaceutical lifecycle.

Learn more at www.aizant.com
For business enquiries write to bd@aizant.com

20/04/2026

At Aizant, we bring together API R&D, formulation development, analytical development, clinical manufacturing, clinical research support, and commercial manufacturing to enable a seamless progression from early development to commercialization.

With dedicated scale up and manufacturing capabilities for various dosage forms, we help bridge critical gaps between development and clinical supply, ensuring continuity, speed, and quality throughout the lifecycle.

Our infrastructure is further strengthened by digital platforms, digital twins, and AI and ML enabled systems, supporting better decision making, process efficiency, and scalable outcomes.

If you are looking for a partner who can support your molecule end to end with reliability and flexibility, this video provides a quick overview of how we deliver.

Watch the video to learn more @ https://www.youtube.com/watch?v=Ed9CztYYFzM

Integrated CDMO Services Across the Drug Development Lifecycle

17/04/2026

We are pleased to welcome Mr. Manabendra Mukhopadhyay to Aizant as Associate Director – Digitalization and Business Process Automation.

With around 19 years of experience in the pharmaceutical industry, he brings expertise in corporate quality assurance across API, formulations, and injectable operations within regulated environments. His experience includes Quality Management Systems (QMS), investigations, compliance, and data integrity.

He also brings exposure to digital and AI-enabled quality systems, contributing to the integration of technology-driven approaches in pharmaceutical quality and operations.

We look forward to his contributions as we continue to strengthen our digital and process capabilities.